Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

BLRXlongRIPorYOLO Mar. 12 at 7:01 PM

$BLRX hi. Been a while. Anyone got a quick synopsis of wtf happening here 😂

1 · Reply

TwongStocks Mar. 12 at 5:42 PM

$BLRX The GLIX1 Phase 1 trial has posted on the clinicaltrials website https://clinicaltrials.gov/study/NCT07464925 A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma Status: Not yet Recruiting Estimated Start: March 2026 Estimated Enrollment: 30 Primary completion: June 2027 Study Completion: Dec 2027 Primary endpoints are Safety Profile (TEAEs) and Maximum Tolerated Dose.

0 · Reply

DiaJay Mar. 11 at 4:14 PM

$BLRX Congrats to Bioline RX for surviving its litigation. i expected the opposite outcome. It will still be difficult for this company to partner with anyone significant. To many terrible decisions to list in the last six years to post regarding BLRX.

0 · Reply

TwongStocks Feb. 27 at 5:21 PM

$BLRX Insiders and Directors of Foreign Private Issuers will have to make Form 3 and Form 4 filings effecting March 18, 2026. Like their counterparts at US companies, they will have to report buys/sells within 2 business days. 10% holders of FPIs are exempt. https://www.sec.gov/newsroom/press-releases/2026-23-sec-adopts-final-rules-holding-foreign-insiders-accountable-act We will finally start seeing Form 4 filings from foreign bio insiders.

1 · Reply

gargoyl Feb. 25 at 3:18 PM

$BLRX 👀 Important, all individuals, entities, investors must do their own “ due diligence “ bio stocks are binary & very risky . The returns sometimes don’t come immediately due to start ups , need raise $$, trials , tribulations, FDA approval, market conditions, geopolitical situations, on and on .. this company has a pipeline worth looking at .. long term 🎯 $18.99 Long the 🦋 👇🏼 https://biolinerx.com/

0 · Reply

gargoyl Feb. 24 at 5:14 PM

$BLRX watch how MM manipulates price today on low volume .. Target 🎯 $18.99 All my posts are opinion only $XBI $IBB

1 · Reply

gargoyl Feb. 23 at 3:11 PM

$BLRX 👀 that's a 70% equivalent of current market cap value.. that’s Phil’s detailed work ✅ quietly coiling for a ripped response, perfect storm would be milestone catalyst while $XBI is ripping.. long the 🦋 🎯 $18.99 $VSTM

0 · Reply

TwongStocks Feb. 23 at 2:39 PM

$BLRX Arbitrator ruled in favor of BLRX against Biokine. https://www.sec.gov/Archives/edgar/data/1498403/000117891326000589/zk2634422.htm On February 22, 2026, in binding arbitration, the arbitrator issued a final award in favor of BioLineRx Ltd. (the “Company”), denying all claims asserted against it by Biokine Therapeutics Ltd. (“Biokine”) and awarding the Company expenses, including legal fees. As previously disclosed, in June 2024, Biokine filed a complaint against the Company alleging breach of contract and the purported failure to make certain payments to Biokine under the Company’s in-licensing agreement with Biokine for motixafortide. The complaint, as subsequently amended, sought damages of approximately $7.2 million and declaratory judgment in favor of Biokine.

1 · Reply

OfficialStocktwitsUser Feb. 20 at 7:57 PM

$BLRX RSI: 33.33, MACD: -0.0420 Vol: 0.10, MA20: 2.99, MA50: 2.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

gargoyl Feb. 20 at 5:57 PM

$BLRX 👀 🦍 It’s about get Interesting up in 👂hear $REGN $PFE $VSTM

0 · Reply

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

2025-11-24T13:01:39.000Z - 3 months ago

BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall

2025-11-24T12:34:08.000Z - 3 months ago

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

Mon, 24 Nov 2025 07:00:00 -0500 - 3 months ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-24T11:11:10.000Z - 3 months ago

Earnings Scheduled For November 24, 2025

2025-11-21T15:01:37.000Z - 3 months ago

BioLine Rx's Earnings: A Preview

Tue, 18 Nov 2025 07:00:00 -0500 - 4 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Mon, 17 Nov 2025 07:00:00 -0500 - 4 months ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Mon, 29 Sep 2025 15:27:41 -0400 - 5 months ago

BioLineRx Ltd. - Special Call

2025-09-29T12:33:46.000Z - 5 months ago

BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy

Mon, 29 Sep 2025 07:00:00 -0400 - 5 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Thu, 14 Aug 2025 10:44:24 -0400 - 7 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Thu, 14 Aug 2025 07:00:00 -0400 - 7 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-08-14T08:32:32.000Z - 7 months ago

Earnings Scheduled For August 14, 2025

Thu, 07 Aug 2025 07:00:00 -0400 - 7 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Fri, 30 May 2025 13:58:03 -0400 - 10 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

2025-05-30T17:58:03.000Z - 10 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

Fri, 30 May 2025 07:00:00 -0400 - 10 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

Tue, 27 May 2025 12:55:23 -0400 - 10 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

Tue, 27 May 2025 07:00:00 -0400 - 10 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

2025-05-27T08:32:09.000Z - 10 months ago

Earnings Scheduled For May 27, 2025

2025-05-26T14:01:50.000Z - 10 months ago

A Look at BioLine Rx's Upcoming Earnings Report

Tue, 20 May 2025 07:00:00 -0400 - 10 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mon, 31 Mar 2025 10:52:17 -0400 - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mon, 31 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

2025-03-28T16:01:40.000Z - 1 year ago

Uncovering Potential: BioLine Rx's Earnings Preview

Mon, 24 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Tue, 21 Jan 2025 07:00:00 -0500 - 1 year ago

BioLineRx Issues Letter to Shareholders

Fri, 17 Jan 2025 07:00:00 -0500 - 1 year ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

2025-01-16T09:43:22.000Z - 1 year ago

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

2025-01-06T19:01:37.000Z - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Mon, 06 Jan 2025 14:01:37 -0500 - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Mon, 06 Jan 2025 08:57:00 -0500 - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering

Mon, 25 Nov 2024 10:58:08 -0500 - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Mon, 25 Nov 2024 07:00:00 -0500 - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

2024-11-25T08:32:08.000Z - 1 year ago

Earnings Scheduled For November 25, 2024

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Thu, 15 Aug 2024 15:03:06 -0400 - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

Tue, 28 May 2024 17:56:01 -0400 - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 2 years ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 2 years ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

BLRXlongRIPorYOLO Mar. 12 at 7:01 PM

$BLRX hi. Been a while. Anyone got a quick synopsis of wtf happening here 😂

1 · Reply

TwongStocks Mar. 12 at 5:42 PM

0 · Reply

DiaJay Mar. 11 at 4:14 PM

0 · Reply

TwongStocks Feb. 27 at 5:21 PM

1 · Reply

gargoyl Feb. 25 at 3:18 PM

0 · Reply

gargoyl Feb. 24 at 5:14 PM

$BLRX watch how MM manipulates price today on low volume .. Target 🎯 $18.99 All my posts are opinion only $XBI $IBB

1 · Reply

gargoyl Feb. 23 at 3:11 PM

0 · Reply

TwongStocks Feb. 23 at 2:39 PM

1 · Reply

OfficialStocktwitsUser Feb. 20 at 7:57 PM

0 · Reply

gargoyl Feb. 20 at 5:57 PM

$BLRX 👀 🦍 It’s about get Interesting up in 👂hear $REGN $PFE $VSTM

0 · Reply

tankwfwf Feb. 19 at 4:27 PM

$BLRX There is an article on the National Library of Medicine website titled Measurable Residual Disease in Hematological Cancers. It gives a well written explanation on what is going on with MRD........

0 · Reply

TwongStocks Feb. 19 at 2:54 PM

$BLRX Aphexda's Phase 4 study (PARADE trial) was also updated recently. https://clinicaltrials.gov/study/NCT07101445 Primary completion changed from Dec 31, 2025 to Dec 31, 2026. Study completion changed from Dec 31, 2026 to Dec 31, 2027. This is a study testing Methylprednisolone vs Dexamethasone-based regimens to help prevent injection site reactions, which is a common side effect caused by Aphexda. Additional details in the quoted post below 👇

0 · Reply

TwongStocks Feb. 19 at 2:46 PM

$BLRX Interesting trial for Aphexda. Study conducted in Washington University in St Louis. Gamida (subsidiary of Ayrmid) is the sponsor. Phase 2 trial testing Aphexda (motixafortide) for Measurable Residual Disease (MRD) Sensitization in Acute Myeloid Leukemia (AML) https://clinicaltrials.gov/study/NCT07392970 NOTE: This is not testing Aphexda as an AML treatment. What they are doing is using Aphexda to measure MRD levels in AML patients after they complete induction treatment. MRD tests are used to detect if any trace amounts of leukemia remain in the bone marrow after a patient undergoes treatment. They are hypothesizing that giving a patient Aphexda before MRD tests will help make the MRD tests more accurate. Not exactly a treatment. However, since the Ayrmid milestone payments are primarily based on annual Aphexda revenue, any additional approvals they can get for Aphexda might help boost Ayrmid's current numbers.

0 · Reply

gargoyl Feb. 18 at 5:11 PM

$BLRX 👀 time is here , ticking 💣 into beast mode. 🦍 the charts , the slow deal, the spoofing, the whole down play , screams coiled by unscrupulous entities want it all .. low float !! Low 🧢 cap!!watch as the word spreads of this 💎 … 🎯 $18.88 Phil is the OG CO “ long the 🦋 $XBI $VSTM

0 · Reply

AfghanBattleRat Feb. 18 at 1:45 AM

$BLRX wow

0 · Reply

BillionerOfKing Feb. 16 at 8:43 PM

$BLRX Current Stock Price: $2.93 Contracts to trade: $3.0 BLRX Feb 20 2026 Call Entry: $0.27 Exit: $0.35 ROI: 28% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

gargoyl Feb. 16 at 2:10 PM

$BLRX 👀 very much , multiple times undervalued, small float , catalyst rich Long the 🦋 yet beast mode 🦍 is eminent, target 🎯 $18 $XBI $VRSN

0 · Reply

Bio_Be_Dirty Feb. 13 at 6:55 PM

$BLRX due for the pop

0 · Reply

gargoyl Feb. 13 at 4:55 AM

$BLRX 👀 target 🎯 $18 https://ir.biolinerx.com/static-files/f1fbb06b-cb0e-4902-b166-f780a049ba38 $XBI $IBB Long the 🦋

0 · Reply

DiaJay Feb. 12 at 5:16 PM

$BLRX 97% loss for 2025 is my story in this shitty scam of a stock. It is ran by an unscrupulous scumbags who I believe would sell out all of Isreal for a dollar. That is honest testimony not an attack.

0 · Reply

BillionerOfKing Feb. 12 at 2:26 PM

$BLRX Current Stock Price: $2.99 Contracts to trade: $3.0 BLRX Feb 20 2026 Call Entry: $0.27 Exit: $0.41 ROI: 53% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

gargoyl Feb. 9 at 8:10 PM

$VSTM $BLRX Boxed them 👇🏼

0 · Reply

Market Cap	11.48M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-31.86%
Debt to Equity Ratio	0.52

Volume	10,400
Avg Vol	14,664
Day's Range	N/A - N/A
Shares Out	4.35M
Stochastic %K	22%
Beta	1.31
Analysts	Strong Sell
Price Target	$20.33